NASDAQ$KRRO
Korro Bio Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported full year 2023 financial results and highlighted recent progress.
Korro Bio reported a strong cash position of $166.1 million and reiterated progress on KRRO-110 and other pipeline candidates.
- On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024.
- Demonstrated the versatility of Korro’s RNA editing platform by generating de-novo protein variants via multiple targets in non-human primates (NHPs).
- Demonstrated greater than 50% editing using GalNAc conjugates in the liver with subcutaneous administration in a preclinical mouse model.
- Ended 2023 with $166 million of cash and cash equivalents, including $117 million of proceeds from a successful private financing completed in November 2023, providing cash runway into 2026.
Headline financials
Revenue & EPS history
Korro Bio · Revenue · Quarterly
$0
Forward guidance
Korro Bio anticipates several milestones in 2024, including a regulatory submission for KRRO-110 in the second half of 2024 and further progression of pipeline programs.
Tailwinds
- Regulatory filing for KRRO-110 in AATD on track for the second half of 2024.
- Anticipated interim clinical readout for KRRO-110 in AATD in the second half of 2025.
- Advancement of KRRO-110 through a potential interim clinical readout.
- Progression of additional product candidates through the Company’s pipeline.
- Demonstration of OPERA applicability across additional tissue types.
Headwinds
- Risks inherent in biopharmaceutical development.
- Risks associated with pre-clinical studies and clinical trials.
- Risks associated with obtaining regulatory approvals and protecting intellectual property.
- Risks associated with general economic conditions.
- The inability to recognize the anticipated benefits of the recently completed merger.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-4.6%
Avg return
Earnings day
+4.3%
Avg return
5 days after
+1.9%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+20.6%
Q4 2023
Best reaction
-79.3%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.3% | -16.3% | -20.5% | |
| Q4 2025 | -0.4% | +14.5% | +20.4% | |
| Q3 2025 | -79.3% | -80.2% | -73.8% | |
| Q1 2025 | +4.1% | -2.0% | -11.8% | |
| Q4 2024 | -5.3% | -5.7% | -1.6% | |
| Q3 2024 | -25.2% | -35.3% | -40.2% | |
| Q2 2024 | +10.4% | +22.1% | +12.4% | |
| Q1 2024 | +5.0% | +8.8% | -15.4% | |
| Q4 2023 | +20.6% | +22.6% | -20.3% | |
| Q3 2023 | +9.4% | +192.6% | +246.3% | |
| Q2 2023 | -4.1% | -1.4% | -39.0% | |
| Q1 2023 | -5.6% | +6.2% | +1.9% | |
| Q4 2022 | +3.1% | -2.4% | -24.2% | |
| Q3 2022 | -5.8% | +4.4% | -11.1% | |
| Q2 2022 | -11.1% | -10.7% | -4.9% | |
| Q1 2022 | +4.0% | +1.6% | -8.0% | |
| Q3 2021 | +3.2% | -3.5% | -17.0% | |
| Q2 2021 | +0.5% | -9.9% | -12.3% | |
| Q1 2021 | -20.3% | -14.6% | -4.6% | |
| Q3 2020 | -6.4% | +4.6% | +59.7% | |
| Q2 2020 | -1.7% | -4.2% | -19.8% | |
| Q1 2020 | -1.1% | +5.1% | +16.0% | |
| Q3 2019 | +4.8% | +3.6% | +11.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro